(3/26, Jenkins) reports researchers found in a phase 1b/2 trial that the combination of lenvatinib and pembrolizumab showed “compelling efficacy” for the treatment of “advanced endometrial carcinoma, regardless of tumor microsatellite instability status.” The researchers found “a 38% objective response rate at 24 weeks among the 108 women with advanced endometrial carcinoma treated with the tyrosine kinase inhibitor and immune checkpoint inhibitor combination, and the median duration of response reached 21.2 months.” The findings were published in the Journal of Clinical Oncology.
